Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 6 days ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire 12 days ago

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

GlobeNewswire November 7, 2024

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

GlobeNewswire October 24, 2024

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

GlobeNewswire October 15, 2024

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire September 30, 2024

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 30, 2024

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

GlobeNewswire August 28, 2024

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

GlobeNewswire August 2, 2024

Vaxart Provides Business Update

GlobeNewswire June 17, 2024

Vaxart Announces $40 Million Underwritten Offering of Common Stock

GlobeNewswire June 13, 2024

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire June 13, 2024

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 23, 2024

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire May 13, 2024

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

GlobeNewswire May 7, 2024

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

GlobeNewswire April 30, 2024

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

GlobeNewswire March 27, 2024

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 20, 2024

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

GlobeNewswire March 14, 2024